Home News Cancer News New Platform Matches Patients to Precision Oncology Trials

New Platform Matches Patients to Precision Oncology Trials

Clinical trial consents happened 55 days sooner for patients using MatchMiner compared with those using non-MatchMiner channels

WEDNESDAY, Oct. 19, 2022 (HealthDay News) — A new open-source platform speeds matching of patients to precision medicine (PM) oncology trials, according to a study published online Oct. 6 in npj Precision Oncology.

Harry Klein, Ph.D., from Dana-Farber Cancer Institute in Boston, and colleagues developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. The MatchMiner capabilities, its deployment at the Dana-Farber Cancer Institute, and its impact on PM trial enrollment are characterized in the study.

The researchers report that from March 2016 through March 2021, 354 PM trials containing a broad range of genomic and clinical eligibility criteria were curated. MatchMiner facilitated 166 trial consents for 159 patients. MatchMiner had a shorter time from genomic sequencing report date to trial consent (55 days shorter; 22 percent earlier) versus patients consented through non-MatchMiner means.

“The combination of this growing body of genomic data and increasing number of precision medicine trials has created a kind of disconnect: finding the right trial for each patient can be a difficult task,” one author said in a statement. “MatchMiner helps bridge that gap.”

Abstract/Full Text

Copyright © 2022 HealthDay. All rights reserved.